



The PSYLECT study

opportunities and pitfalls of digitizing a clinical trial in a LMIC

Andre Russowsky Brunoni, MD, PhD

Associate Professor, Department of Psychiatry, University of São Paulo Medical School University of São Paulo São Paulo, Brazil <u>brunoni@usp.br</u>



Disclosure



• I have no conflicts of interest regarding the topics of this presentation.







• The Psylect clinical trial: background and rationale

• Digitalization and ethical challenges



Major Depressive Disorder




• High prevalence

• Responsible for the main burden of all mental disorders


• Presents high rates of treatment resistance

• Interventions have low scalability









tDCS

The ELECT-TDCS trial

PATIENTS

- 245 patients, 18-65 years
- HDRS ₁₇ > 17
- No ADs at baseline

INTERVENTIONS


- Escitalopram 20 mg/day.
- 22 tDCS sessions
- Non-inferiority design with


placebo group

DESIGN

•

Active tDCS Placebo pill Sham tDCS Escitalopram Sham tDCS Placebo pill






Escitalopram > tDCS > placebo












Internet-based therapy with behavioural components






Digitizing clinical trials Nature Digital Health, O. T. Inan¹[™], P. Tenaerts², S. A. Prindiville³, H. R. Reynolds⁴, D. S. Dizon⁵, K. Cooper-Arnold^{6,21}, M. Turakhia⁷, M. J. Pletcher⁸, K. L. Preston⁹, H. M. Krumholz ^{10,11,12}, B. M. Marlin ¹³, K. D. Mandl ¹⁴, P. Klasnja¹⁵, B. Spring¹⁶, E. Iturriaga¹⁷, R. Campo¹⁷, P. Desvigne-Nickens¹⁷, Y. Rosenberg¹⁷, S. R. Steinhubl ¹⁸ and R. M. Califf^{19,20} **Digital recruitment** Digital data collection Digital clinical trial Digital data analysis


PERSPECTIVE

OPEN

Check for updates

HCFMUSP










Non-Maleficence
















• Only people who can use digital devices can participate in the study. Again, a "digital exclusion" might occur.

• On the other hand, accessibility is expanded by mitigating daily commutes to/from the clinical centers. Also, this allows that the treatment occurs in non-business hours.






Lower standard-of-care

- Participants can send messages to the clinical trial team.
- However, answering questions 24/7 imposes a high burden to the team.
- Developing chatbots for simple questions (the most common ones) would help logistically, but could this decrease the standard of care?









Autonomy



 The bioethical principle of autonomy has been discussed for a long time in vulnerable populations such as those with mental disorders.

• Digital studies might collect lots of sensitive data such as information related to mental health, further exposing these patients.







Use of portable mobile Health device can lead to misuse, unitentionally or not, overuse, lack of training or device malfunctioning.

Who is accountable in these cases?







With great power

comes great(er) responsabilities





Muito obrigado!

(thank you very much)

Andre Brunoni, MD, PhD brunoni@usp.br